SNX-BAR proteins 5 and 6 are required for NCOA7-AS antiviral activity against influenza A virus

This study reveals that the antiviral activity of NCOA7-AS against influenza A virus depends on its interaction with the V-ATPase and the essential recruitment of SNX5/6 proteins, which bind to NCOA7-AS via a structural motif similar to that of known SNX5/6 cargoes to facilitate viral membrane fusion inhibition.

The Gist

The Big Picture: A Cellular "Security Guard" vs. The Flu Virus

Imagine your body is a high-tech fortress. Inside, there are specialized security guards called NCOA7-AS. Their job is to stop intruders, specifically the Influenza A virus (the flu).

The flu virus is a sneaky thief. To break into a cell, it doesn't just kick down the front door; it uses a "delivery truck" called an endosome (a bubble inside the cell) to sneak in. Once inside the bubble, the virus needs the environment to become very acidic (like a sour lemon) to unlock its own doors and release its stolen goods (its genetic code) into the cell.

NCOA7-AS is a smart guard that knows this trick. It works by making the delivery bubbles too acidic, too fast. This confuses the virus, causing its "keys" to jam before it can unlock the door. The virus gets stuck and dies.

However, scientists didn't know exactly how NCOA7-AS managed to turn up the acidity so effectively. This paper solves that mystery by finding the guard's two main helpers.

---

The Two Key Helpers

The researchers discovered that NCOA7-AS doesn't work alone. It needs a team of two specific partners to do its job:

1. The V-ATPase (The Acid Pump): Think of this as the water pump that fills the delivery bubble with acid. NCOA7-AS grabs onto this pump and cranks the dial to "maximum."
2. SNX5 and SNX6 (The Delivery Drivers): These are the new heroes of the story. Think of them as specialized delivery drivers who usually move packages from the front door (endosomes) back to the warehouse (the Golgi network).

The Discovery: How They Work Together

The scientists found that NCOA7-AS is like a universal remote control that needs two things to work:

• It needs to plug into the Pump (V-ATPase) to get the power.
• It needs to plug into the Drivers (SNX5/6) to get the remote to the right place.

The "Plug" Analogy

Imagine NCOA7-AS is a remote control.

• The V-ATPase connection: The remote has a battery compartment. If you break the battery connection (by changing one tiny letter in the protein's code, called Glycine 91), the remote has no power. The virus slips in, and the cell gets infected.
• The SNX5/6 connection: The remote also has a specific antenna that needs to dock with a satellite dish (the SNX proteins). The scientists found a specific spot on the remote, a tiny hook made of a chemical called Tyrosine 14, that locks into the satellite dish.

If you break that hook (by changing Tyrosine 14 to something else), the remote can still have batteries (it can still talk to the pump), but it can't connect to the satellite dish. Without the dish, the signal doesn't go through, the acid pump doesn't get the "crank it up" order, and the virus wins.

The "Lock and Key" Breakthrough

The most exciting part of the paper is that the scientists actually built a 3D model (a crystal structure) of the remote control (NCOA7-AS) locking into the satellite dish (SNX5).

They found that the shape of the "hook" on the remote fits perfectly into a specific groove on the dish. It's like a Puzzle Piece.

• The hook is made of a specific amino acid (Tyrosine 14).
• The groove has a matching spot (Phenylalanine 136).
• When they snap together, they form a strong, hydrophobic (water-repelling) bond, like two magnets sticking together.

The researchers proved this by swapping out the hook. When they replaced the hook with a different shape, the puzzle pieces wouldn't fit, the remote stopped working, and the flu virus was able to infect the cell again.

Why This Matters

This study is like finding the missing instruction manual for a security system.

• Before: We knew NCOA7-AS stopped the flu, but we didn't know how it held onto the machinery.
• Now: We know it needs SNX5 and SNX6 to act as a bridge. It uses these proteins to hijack the cell's acid pumps and turn them up to 11, creating a "sour trap" that kills the virus.

Summary in a Nutshell

The flu virus tries to sneak into your cells using a delivery bubble. Your body has a guard (NCOA7-AS) that stops the virus by making that bubble too sour. This guard needs two helpers: a pump (V-ATPase) to make the sourness, and two drivers (SNX5/6) to help the guard grab the pump. The scientists found the exact "handshake" (the Tyrosine 14 hook) that lets the guard hold onto the drivers. Without this handshake, the guard is useless, and the flu wins.

This discovery opens the door to designing new drugs that could boost this "handshake," helping our bodies fight off the flu more effectively in the future.

Technical Summary

1. Problem Statement

Influenza A Virus (IAV) entry relies on endocytosis and the subsequent acidification of the endosomal lumen by the vacuolar ATPase (V-ATPase). This acidification triggers hemagglutinin (HA) fusion and viral uncoating. The interferon-induced protein NCOA7-AS (a short isoform of Nuclear Receptor Coactivator 7) has been identified as a potent antiviral factor that inhibits IAV entry by promoting the overacidification of the endolysosomal pathway.

However, the precise molecular mechanism by which NCOA7-AS achieves this was unclear. While it was known to interact with the V-ATPase, the specific cellular partners facilitating this interaction and the structural basis for its antiviral function remained undefined. Understanding these mechanisms is crucial for elucidating host defense strategies against respiratory viruses.

2. Methodology

The researchers employed a multi-disciplinary approach combining cell biology, structural biology, biochemistry, and virology:

• Proteomics: Mass spectrometry (MS) was used to identify cellular binding partners of FLAG-tagged NCOA7-AS in U87-MG cells.
• Genetic Manipulation:
  • CRISPRi: Dual sgRNA systems were used to knock down SNX1/2 and SNX5/6 in A549 cells to assess functional redundancy.
  • Site-Directed Mutagenesis: Key residues in NCOA7-AS (G91, Y14) and SNX5 (F136) were mutated to alanine or phenylalanine to disrupt specific interactions.
• Virology:
  • Single-cycle infections: Using Nanoluciferase-encoding IAV strains (H1N1 and H3N2) to measure entry efficiency.
  • Multi-cycle growth curves: To assess viral replication over time.
• Cellular Phenotyping: Flow cytometry using LysoTracker (volume) and LysoSensor (pH) to quantify endolysosomal acidification and expansion.
• Biochemistry:
  • Co-immunoprecipitation (Co-IP): To validate physical interactions in cells.
  • GST Pull-downs: To confirm direct protein-protein interactions using recombinant proteins.
  • Microfluidic Diffusional Sizing (MDS): To measure dissociation constants ($K_d$) between interacting partners.
• Structural Biology:
  • X-ray Crystallography: A chimeric protein (PX-SNX5 fused to NCOA7-AS N-terminal domain) was crystallized to solve the high-resolution structure of the complex.
  • AlphaFold Modeling: Used to predict the structure of NCOA7-AS domains.

3. Key Contributions & Results

A. Validation of V-ATPase Interaction

• The study confirmed that NCOA7-AS interacts with V-ATPase V1 subunits (ATP6V1A, B2, E1).
• Critical Residue: Glycine 91 (G91) in the TLDc domain of NCOA7-AS is essential for V-ATPase binding. The G91A mutant failed to bind V-ATPase, lost the ability to induce endolysosomal overacidification, and exhibited no antiviral activity against IAV. This proves V-ATPase engagement is a prerequisite for the antiviral phenotype.

B. Identification of SNX-BAR Partners

• Mass spectrometry identified SNX1, SNX2, SNX5, and SNX6 as novel binding partners of NCOA7-AS.
• Functional Requirement: CRISPRi-mediated depletion of SNX1/2 or SNX5/6 abolished the antiviral activity of NCOA7-AS and prevented endolysosomal overacidification.
• Specificity: While SNX1/2/5/6 were all identified, SNX5 and SNX6 were shown to be the primary direct interactors. Depletion of SNX5/6 had a more direct effect on NCOA7-AS function compared to SNX1/2, which also impacted NCOA7-AS expression levels indirectly.

C. Structural Basis of Interaction

• Direct Binding: NCOA7-AS interacts directly with the PX domains of SNX5 and SNX6 via its N-terminal domain (NTD), not the TLDc domain.
• Crystal Structure: The structure of the PX-SNX5/NCOA7-AS-NTD complex revealed that the NTD forms a $\beta$-hairpin that binds to the PX domain of SNX5.
• Key Interface: The interaction mimics known SNX5 cargoes (like CI-MPR). A critical hydrophobic interaction occurs between Tyr14 (Y14) of NCOA7-AS and Phe136 (F136) of SNX5.
• Validation: Mutating Y14 to Alanine (Y14A) abolished binding to SNX5/6 and eliminated antiviral activity. Conversely, the conservative Y14F mutation retained binding and full antiviral function. The reciprocal mutation F136A in SNX5 significantly increased the $K_d$ (weakened binding).

D. Mechanism of Action

The study proposes a model where NCOA7-AS acts as a molecular bridge:

1. NCOA7-AS binds SNX5/6 via its N-terminal domain (Y14-F136 interaction).
2. NCOA7-AS simultaneously binds the V-ATPase via its TLDc domain (G91 interaction).
3. This complex formation leads to the overacidification of the endolysosomal compartment.
4. The altered pH environment disrupts the delicate pH gradient required for IAV membrane fusion and uncoating, thereby blocking viral entry.

4. Significance

• Mechanistic Insight: This study resolves the "black box" of NCOA7-AS function, demonstrating that its antiviral activity is not solely dependent on V-ATPase binding but requires the recruitment of SNX-BAR proteins (specifically SNX5/6).
• Structural Biology: It provides the first high-resolution crystal structure of an NCOA7-AS complex, defining the specific residues (Y14 and G91) that are critical for its dual interaction with SNXs and V-ATPase.
• Therapeutic Potential: Identifying these specific host factors and critical residues offers new targets for antiviral drug development. Disrupting the NCOA7-AS/SNX5/6 interface could potentially modulate host defense mechanisms, while understanding how viruses might evade this pathway could inform broad-spectrum antiviral strategies.
• Broader Context: The findings highlight the complexity of TLDc-containing proteins, suggesting their activity is modulated by specific cellular partners (SNXs) rather than acting in isolation, challenging previous in vitro models that suggested TLDc domains simply inhibit V-ATPase assembly.

In conclusion, the paper establishes that SNX5 and SNX6 are essential co-factors for NCOA7-AS-mediated antiviral defense against Influenza A, acting through a specific structural interface that drives endolysosomal hyperacidification to block viral entry.